ArticleBMJ open respiratory research2026
Use of high-frequency chest wall oscillation therapy in infants: protocol for a feasibility randomised controlled clinical trial.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSince the inflammatory response increases the production and accumulation of mucus in the airways during respiratory infections, conventional and unconventional techniques of secretion removal are used. High-frequency chest wall oscillation is an effective strategy for secretion removal; however, it presents barriers due to the high cost. In Brazil, the Expector was developed using a kangaroo-vest interface as an accessible alternative; however, studies are needed to evaluate the use of Expector in infants. The aim of this study was to assess the feasibility and usability of the Expector device in healthy infants. METHODS AND ANALYSIS: For this feasibility randomised controlled clinical trial, 30 participants aged 3-6 months will be divided into three groups. Two experimental groups will use the Expector device (kangaroo baby-carrier version) with different configurations of the minivibrating motors (ie, totally activated and upper half of motors activated). The device will be deactivated for the control group. The following parameters will be assessed before the test, every 5 min during 15 min of device use and for 15 min after its use: heart rate, respiratory rate, peripheral oxygen saturation, pulmonary auscultation, sleep/wakefulness state, pain and parental satisfaction. Data will be described using measures of central tendency and dispersion and absolute and relative frequencies. Statistical analysis will be performed using correlation and intra- and intergroup comparisons. This study will generate preliminary evidence regarding the feasibility of Expector (kangaroo baby-carrier version) for infants and allow randomised and controlled studies using this technology. ETHICS AND DISSEMINATION: The Ethics Committee of the Faculty of Health Sciences of Trairi of the Federal University of Rio Grande do Norte approved this study (Number 5636504). Findings will be disseminated through peer-reviewed journal publications, scientific conference presentations and knowledge translation to the public via social media. TRIAL REGISTRATION NUMBER: This feasibility randomised controlled clinical trial was registered in the Brazilian Registry of Clinical Trials (REBEC) (Number RBR-5r8v8qz).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.